Needham & Company Raises Price Target to $70 on Cepheid (CPHD) Following 2Q15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Wedbush Cuts Price Target to $66 on Cepheid (CPHD) Following 2Q15
July 24, 2015 10:13 AM EDTWedbush reiterated an Outperform rating on Cepheid (NASDAQ: CPHD), and cut the price target to $66.00 (from $67.00), following 2Q15 results. CPHD reported 2Q15 sales of $133 MM compared to $131 MM estimates. Reported GAAP EPS was ($0.23), compared with consensus EPS loss of ($0.21).
Analyst Zarak Khurshid commented,... More
Cepheid (CPHD) PT Raised to $72 at MKM Partners
July 24, 2015 7:22 AM EDTMKM Partners analyst Peter Lawson reiterated a Buy rating and boosted his price target on Cepheid (NASDAQ: CPHD) to $72.00 (from $65.00) following Q2 results.
Lawson commented, "We are reiterating our Buy rating and raising our PT to $72 following 2Q results. CPHD beat... More
UPDATE: Evercore ISI Downgrades Cepheid (CPHD) to Sell; Analyst Sees Risk of Multiple Compression
July 24, 2015 6:46 AM EDT(Updated - July 24, 2015 8:28 AM EDT)
Evercore ISI downgraded Cepheid (NASDAQ: CPHD) from Hold to Sell with a price target of $53.50. Analyst Vijay Kumar noted a 42% rally since April and warned slowing growth and Q4 risk could lead to multiple compression.
"Shares of CPHD have rallied ~42% since reporting earnings on 4/23 vs. the S&P 500 at ~12%, largely due to strength in 1Q commercial clinical revenues, optimism around new product pipeline... More
Cepheid (CPHD) Tops Q2 EPS by 15c
July 23, 2015 4:41 PM EDTCepheid (NASDAQ: CPHD) reported Q2 EPS of ($0.06), $0.15 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $132.5 million versus the consensus estimate of $130.7 million.
For earnings history and earnings-related data on Cepheid (CPHD) click here.
... MoreTrading Radar for 7/23: GM (GM), Visa (V), 3M (MMM), Caterpillar (CAT), Comcast (CMCSA), McDonald's (MCD) Report
July 22, 2015 3:01 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
3M Co. (NYSE: MMM) - consensus EPS $2.00
A.O. Smith (NYSE: AOS) - consensus EPS $0.66
ABB Ltd. (NYSE: ABB) - consensus EPS $0.26
AMAG Pharma (Nasdaq: AMAG) - consensus EPS $1.13
Adeptus Health (Nasdaq:... More
